eXoZymes closes $639,990 follow-on offering with MDB Capital

eXoZymes Inc. entered a Placement Agent Agreement on June 30, 2026 with Public Ventures LLC, doing business as MDB Capital, as exclusive placement agent. The agreement authorized the sale to an investor of up to an aggregate of 35,555 units, consisting of 71,110 shares of common stock and 35,555 warrants to purchase up to an aggregate of 35,555 shares of common stock.¹

The price per Unit was $18.00. The Shares and Warrants were immediately separable and issued separately but purchased together as a unit. The purchase price of one Share was the equivalent of $8.99 and of the Warrant $0.02.¹ The securities offered had the same terms as those sold in the firm commitment underwriting led by MDB on June 5, 2026.¹

The offering closed on June 30, 2026, with gross proceeds to the company of $639,990, before commissions of $44,799 and other expenses of approximately $30,000.¹ Net proceeds are intended to further develop opportunities tied to the N-trans-caffeoyltyramine business and related products, next in line products, research and development, and general corporate purposes including working capital and capital expenditures.¹

As part of the deal, MDB, as placement agent, was issued a warrant to purchase 10,666 shares of common stock, exercisable at $11.24 per share, from December 30, 2026, until June 30, 2031.¹

On the warrant terms, each Warrant becomes exercisable commencing June 5, 2027, at an exercise price of $11.24 per share and will expire on June 5, 2031, and may be called for redemption starting June 5, 2027 once shares trade at or above $17.98 on any 20 trading days within a 30 trading day period.¹

The offering was made under the company's effective shelf registration statement on Form S-3, File No. 333-292781, declared effective January 23, 2026.¹